Acasti Pharma EBITDA Margin 2014-2024 | GRCE
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Acasti Pharma (GRCE) over the last 10 years. The current EBITDA margin for Acasti Pharma as of June 30, 2024 is .
| Acasti Pharma EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2016-11-30 |
$0.00B |
$-0.00B |
inf% |
| 2016-05-31 |
$0.00B |
$-0.00B |
inf% |
| 2016-03-31 |
$0.00B |
$-0.00B |
inf% |
| 2015-12-31 |
$0.00B |
$-0.00B |
inf% |
| 2015-09-30 |
$0.00B |
$-0.01B |
inf% |
| 2015-06-30 |
$0.00B |
$-0.01B |
inf% |
| 2015-03-31 |
$0.00B |
$-0.01B |
inf% |
| 2014-12-31 |
$0.00B |
$-0.01B |
inf% |
| 2014-06-30 |
$0.00B |
$-0.01B |
inf% |
| 2014-03-31 |
$0.00B |
$-0.01B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
